Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Peripheral blast count at apheresis as a risk factor for survival following tisagenlecleucel in children and young adults

View Full Paper
Ask AI
Bookmark
Share

Authors

KMKristen MillerANAndrew NicklawskyHPHolly Pacenta

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows that peripheral blasts at apheresis influence disease burden and outcomes in children with R/R B-ALL treated with CAR T therapy.

Key Points

  • This research investigates the influence of peripheral blast count at apheresis on survival outcomes following CAR T cell therapy in pediatric patients.
  • Retrospective analysis of 162 pediatric patients from the Pediatric Real-World CAR Consortium
  • Evaluated outcomes like day 28 response, event-free survival, and overall survival based on peripheral blasts
  • Utilized multivariable analysis to account for disease burden at infusion
  • Presence of peripheral blasts at apheresis linked to inferior event-free survival (27% vs. 55% at 12 months)
  • Overall survival was also lower for those with peripheral blasts (55% vs. 78% at 12 months)
  • Higher blast percentage at apheresis did not correlate with increased hazard of death (HR = 1.11, p = 0.25)

Cite This Study

Miller et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d536https://doi.org/10.1182/blood-2025-7638
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Peripheral blood B-cell early regeneration predicts clinical relapse and guides preemptive therapy after CAR-T treatment in acute lymphoblastic leukemia2025
  2. 2Identification of independent prognostic factors in relapsed pediatric B-ALL patients receiving CD19 CAR-T without consolidative HSCT.2026
  3. 3Pre-transplant CAR T-cell therapy is associated with inferior survival and increased non-relapse mortality in pediatric B-ALL: A single-center retrospective analysis2025
  4. 4Targeted salvage therapy improves survival in B-ALL relapsing after CD19 CAR-T: A multi-institutional study2025
  5. 5Intention-to-treat outcomes utilising a stringent event definition in children and young people treated with tisagenlecleucel for r/r ALL through a national access scheme2024 · 20 citations